Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Pseudomyxoma Peritonei 1Ovarian Neoplasms 1Osteosarcoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Hearing Loss 1Familial ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 14Gemcitabine 6Filgrastim 6fludarabine 5Methotrexate 5Leucovorin 5Granulocyte Colony-Stimulating Factor 5Zoledronic Acid 4Temozolomide 4Mesna 4Irinotecan 4Ifosfamide 4Etoposide 4Cisplatin 4Carboplatin 4pembrolizumab 3fludarabine phosphate 3Doxorubicin 3Biopsy 3tanespimycin 2poly ICLC 2pegfilgrastim 2lorukafusp alfa 2liposomal doxorubicin 2dinutuximab 2cabozantinib 2belinostat 2Topotecan 2Thalidomide 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Osteosarcoma × Acetylcysteine × Clear all
NCT02094625 2023-04-18

NAC to Prevent Cisplatin-induced Hearing Loss

Children's Hospital Los Angeles

Phase 1 Completed
52 enrolled
GastrointestinalSarcoma

Liver Neoplasms, Osteosarcoma, Neuroectodermal Tumors, Primitive, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡